Answers are grounded in this paper and cite their sources.
In a discussion, Kromann reveals challenges in vaccine manufacturing and regulation affecting preparedness efforts.
“Standardized manufacturing platforms can bring us closer to meeting the 100 Days Mission, but regulatory approval remains a major barrier.”Charlotte Barker, Commissioning Editor, Vaccine Insights , speaks with Ingrid Kromann, Senior Advisor, Process Development and Manufacturing, CEPI, to gain insights on the scientific, operational, and policy challenges shaping the future of outbreak preparedness.
No takes yet. Share an insight, caveat, or question.
Ingrid Kromann (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: